Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Zacks Investment Research
Alphatec (ATEC) Q3 Earnings and Revenues Lag EstimatesAlphatec (ATEC) reported quarterly earnings of $0.09 per share, missing the consensus estimate of $0.11, with revenues also falling short of expectations. The stock has declined 45.6% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Instruments industry ranks in the bottom 40% of Zacks industries, suggesting broader sector weakness.
The Motley Fool
Alphatec CEO Miles Patrick Purchases 115,000 Shares for $1 Million. Is the Medical Tech Stock Now a Buy?Alphatec Holdings CEO Miles Patrick purchased approximately 115,000 shares worth $1 million at a weighted average price of $8.81 per share on September 10, 2026. This insider buy increased his total beneficial ownership to 6.2 million shares worth $54.41 million.
The article interprets this as a bullish signal, noting that insider purchases typically indicate confidence in future stock price appreciation. The company reported strong Q2 results with 15% sales growth and expanding surgeon adoption of its spinal surgery solutions.
Headlines open the publisher's site.
